Dicycloalkyl urea glucokinase activators
View Patent ↗Dicycloalkyl urea glucokinase activators compounds are glucokinase inhibitors useful for the treatment of diabetes. (I)
1. A compound of formula (I)
wherein R 1 is
and R 2 is cyclohexyl; and
A is
and
R 5 is selected from the group consisting of C 3-6 -alkenyloxy, aryloxy-C 1-6 -alkyl, C 3-8 -cycloalkyl-C 1-6 -alkyloxy-C 1-6 -alkyl, aryl-C 1-6 -alkyloxy-C 1-6 -alkyl, heteroaryl-C 1-6 -alkyloxy-C 1-6 -alkyl, C 3-6 -alkenylthio, arylthio-C 1-6 -alkyl, C 3-8 -cycloalkyl-C 1-6 -alkylthio-C 1-6 -alkyl, or heteroaryloxy-C 1-6 -alkyl, each of which is optionally substituted with one or more substituents independently selected from R 12 , and wherein each aryl is phenyl and heteroaryl is pyridyl; and
R 12 is halogen, cyano, hydroxy, carboxy, —CF 3 , C 1-6 -alkyloxy, C 3-8 -cycloalkyloxy, aryloxy, aryl-C 1-6 -alkyloxy or C 1-6 -alkyl; and
R 8 is selected from halogen, carboxy, —CF 3 , —S—CH 3 , —S—CH 2 CH 3 , —S—CH 2 CH 2 CH 3 , methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, methoxy, ethoxy, —CH 2 —C(O)—O—CH 3 , —CH 2 —C(O)—O—CH 2 CH 3 , —CH 2 CH 2 —C(O)—O—CH 3 , —CH 2 CH 2 —C(O)—O—CH 2 CH 3 , —CH 2 —O—C(O)—CH 3 , —CH 2 —O—C(O)—CH 2 CH 3 , —CH 2 CH 2 —O—C(O)—CH 3 , —CH 2 CH 2 —O—C(O)—CH 2 CH 3 , —C(O)—O—CH 3 , —C(O)—O—CH 2 CH 3 , each of which is optionally substituted with one or more substituents independently selected from R 16 ; or heteroarylthio, wherein heteroaryl is pyridyl or imidazolyl, each optionally substituted on the heteroaryl part with one or more substituents independently selected from R 17 , or pyrrolidinyl, piperidyl, piperazinyl, or morpholinyl, each of which is optionally substituted with one or more substituents independently selected from R 16 ; or —S(O) 2 —NR 19 R 20 or —S(O) 2 —R 21
R 16 and R 17 are independently C 1-6 -alkyl, halogen, nitro, cyano, hydroxy, carboxy, oxo, —CF 3 , carboxy-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, —C 1-6 -alkyl-C(O)—O—C 1-6 -alkyl, —C 1-6 -alkyl-C(O)—NR 19 R 20 , —C(O)—O—C 1-6 -alkyl, —C(O)—C 1-6 -alkyl-C(O)—C 1-6 -alkyl, —NR 19 R 20 , —NHS(O) 2 C 1-6 -alkyl, —NHS(O) 2 CF 3 , —NHS(O) 2 CH 2 CF 3 , —C(O)NR 19 R 20 , —S(O) 2 C 1-6 -alkyl, —S(O) 2 CF 3 , —S(O) 2 CH 2 CF 3 or —S(O) 2 NR 19 R 20 ; and
R 19 and independently represent hydrogen, methyl, ethyl, or propyl, S(O) 2 —CH 3 , or R 19 and R 20 together with the nitrogen to which they are attached form a 3 to 8 membered heterocyclic ring with the said nitrogen atom, wherein the heterocyclic ring is pyrrolidyl, piperidyl, piperazinyl, homopiperazinyl, or morpholinyl, the heterocyclic ring is optionally substituted with one or more substituents independently selected from R 24 ; and
R 21 is selected from carboxy-methyl, carboxy-ethyl, or carboxy-propyl; and
R 24 is halogen, carboxy, C 1-6 -alkyl, carboxy-C 1-6 -alkyl, or —C(O)—O—C 1-6 -alkyl; and
as well as any salt hereof with a pharmaceutically acceptable acid or base, or any optical isomer or mixture of optical isomers, racemic mixture, or any tautomeric forms thereof.
2. A compound according to claim 1 wherein R 5 is selected from the group consisting of C 3-6 -alkenyloxy, phenyloxy-C 1-6 -alkyl, benzyloxy-C 1-6 -alkyl, C 3-8 -cycloalkyl-C 1-6 -alkyloxy-C 1-6 -alkyl.
3. A compound according to claim 2 wherein R 5 is selected from the group consisting of C 3-4 -alkenyloxy, phenyloxy-methyl, benzyloxy-methyl, or cyclopropyl-methoxymethyl.
4. A compound according to claim 1 wherein R 12 is halogen, cyano, hydroxy, carboxy, —CF 3 , methoxy, ethoxy, propoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, phenoxy, benzyloxy, phenyl-ethyloxy, phenyl-propoxy, methyl, ethyl or propyl.
5. A compound according to claim 4 wherein R 12 is halogen, carboxy, ethoxy, propoxy, cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy, cycloheptyloxy, phenoxy, benzyloxy, phenyl-ethyloxy, phenyl-propoxy, methyl, ethyl or propyl.
6. A compound according to claim 1 wherein R 8 is selected from Cl, —S—CH 3 , —S—CH 2 CH 3 , —S—CH 2 CH 2 CH 3 , —S—CH(CH 3 ) 2 , —S—CH 2 CH(CH 3 ) 2 , methyl, or ethyl, each of which is optionally substituted with one or more substituents independently selected from R 16 ; —S(O) 2 —NR 19 R 20 or —S(O) 2 —R 21 .
7. A compound according to claim 1 wherein R 16 and R 17 are independently C 1-6 -alkyl, halogen, hydroxy, oxo, carboxy, —CF 3 , carboxy-C 1-6 -alkyl, hydroxy-C 1-6 -alkyl, —C 1-6 -alkyl-C(O)—O—C 1-6 -alkyl, —C(O)—O—C 1-6 -alkyl, —NR 19 R 20 , —C(O)NR 19 R 20 or —S(O) 2 —C 1-6 -alkyl.
8. A compound according to claim 7 wherein R 16 and R 17 are independently methyl, ethyl, propyl, isopropyl, isobutyl, halogen, hydroxy, oxo, carboxy, —CF 3 , carboxy-methyl, carboxy-ethyl, carboxy-propyl, hydroxy-methyl, hydroxy-ethyl, hydroxy-propyl, —CH 2 —C(O)—O—CH 3 , —CH 2 —C(O)—O—CH 2 CH 3 , —CH 2 CH 2 —C(O)—O—CH 3 , —CH 2 CH 2 —C(O)—O—CH 2 CH 3 , —C(O)—O—CH 3 , —C(O)—O—CH 2 CH 3 , —C(O)—O—CH 2 CH 2 CH 3 , or —S(O) 2 CH 3 .
9. A compound according to claim 8 wherein R 16 and R 17 are independently methyl, ethyl, propyl, isopropyl, isobutyl, halogen, oxo, carboxy, carboxy-methyl, carboxy-ethyl, carboxy-propyl, hydroxy-methyl, hydroxy-ethyl, hydroxy-propyl, —CH 2 —C(O)—O—CH 3 , —CH 2 —C(O)—O—CH 2 CH 3 , —CH 2 CH 2 —C(O)—O—CH 3 , —CH 2 CH 2 —C(O)—O—CH 2 CH 3 , —C(O)—O—CH 3 , —C(O)—O—CH 2 CH 3 , —C(O)—O—CH 2 CH 2 CH 3 , or —S(O) 2 CH 3 .
10. A compound according to claim 7 wherein R 16 and R 17 are independently C 1-6 -alkyl, carboxy, —NR 19 R 20 , —C(O)—O—C 1-6 -alkyl, —S(O) 2 CH 3 or —C(O)NR 19 R 20 .
11. A compound according to claim 10 wherein R 16 or R 20 are carboxy.